FDA Grants Full Approval to Blinatumomab for B-cell Precursor ALL

The FDA's full approval of blinatumomab (Blincyto) marks a significant advancement in the treatment of adults and children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), irrespective of Philadelphia chromosome (Ph) status. This decision was informed by the phase III TOWER study, which demonstrated a median overall survival (OS) of 7.7 months with blinatumomab versus 4 months with standard chemotherapy for patients with Ph-negative relapsed/refractory B-cell precursor ALL. The treatment reduced the risk of death by 29% compared to standard chemotherapy.

Additionally, the phase II ALCANTARA trial supported the efficacy of blinatumomab in patients with Ph-positive relapsed/refractory B-cell precursor ALL, showing a median OS of 7.1 months. A significant proportion of patients achieved a complete response or complete response with partial hematological recovery, with a high rate of minimal residual disease-negative status among responders.

Blinatumomab is administered in 6-week cycles, with patients receiving dexamethasone prior to treatment to prevent cytokine release syndrome. The treatment's safety profile was consistent with previous studies, with similar adverse event rates between the blinatumomab and chemotherapy arms. However, blinatumomab showed a lower incidence of severe neutropenia and infections compared to standard chemotherapy.

The approval underscores the importance of blinatumomab as a treatment option for patients with aggressive hematologic malignancies, offering improved response rates and survival outcomes over traditional chemotherapy. The FDA's decision also highlights the need for a risk evaluation and mitigation strategy (REMS) program to manage the risks associated with cytokine release syndrome and neurotoxicity.